Gapping up
In reaction to earnings/guidance:
- SNOW +12.9%, FIVE +8.9%, ZUO +4.7%, SIG +2.2%, OKTA +1.5%, GMS +1.5%, TD +1.1%, AI +1%
Other news:
- VIR +15.3% (Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations New SARS-CoV-2 Variant)
- HGEN +9.7% (The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results)
- XOS +5.1% (announced the receipt of a purchase order for Xos last mile delivery vehicles from Route Consultant a premier broker and consultant for FedEx Ground contractors)
- ACTD +3.9% ( OPAL Fuels to list on Nasdaq through combination with ArcLight Clean Transition Corp. II)
- RDS.A +3.7% (commences shareholder distributions from Permian business sale proceeds)
- WNC +3.6% (backlog grows to a record $2.3 bln during NovQ)
- RRD +3.3% (board decides that Chatham acqusition propsal is superior to Atlas deal)
- TRIT +3.3% (provides update on independent audit)
- SWIR +3.2% (names new chair of board)
- CLVT +2.7% (completes acquisition of ProQuest; also reaffirms FY21 guidance and provides combined outlook for FY22; also names new CFO)
- CHK +2.6% (authorizes $1 bln repurchase of common stock and/or warrants from time to time)
- CLBK +1.5% (announces merger agreement with RSI Bank)
- AIRC +1.4% (files mixed securities shelf offering)
- BOAS +1.4% (Selina and BOA Acquisition Corp. have entered into a definitive business combination agreement that will result in Selina becoming a publicly listed company)
- CVX +1.1% (announces $15 bln capital and exploratory budget for 2022; also raises its share buyback guidance range to $3-5 bln/yr)
Analyst comments:
- ALV +2.6% (upgraded to Outperform from Peer Perform at Wolfe Research)
- CUBE +2.3% (upgraded to Outperform from Mkt Perform at Raymond James)
- GGG +1.2% (upgraded to Outperform from Mkt Perform at William Blair)